Cosmos Health Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $29.9M
- Price
- $0.2976
- % Change (Daily % change from the live per-ticker quote feed.)
- -7.26%
- Volume
- 664.4K
About
Cosmos Health Inc. functions as a vertically integrated pharmaceutical firm, providing its own line of branded and generic medicines, nutraceuticals, non-prescription drugs, healthcare and infant products, medical devices, and various other goods. These are distributed via its established channels and an e-commerce marketplace. The company actively seeks, obtains, develops, and commercializes solutions designed to improve patients' well-being and health outcomes. Supporting these operations, it maintains distribution centers in both Greece and the United Kingdom, alongside a dedicated warehousing facility. Its clientele includes wholesale pharmaceutical distributors and independent retail pharmacies. Cosmos Health Inc. was established in 2009 and has its headquarters in Chicago, Illinois.
Quick stats
Shares outstanding100.6M
Computed float77.9M
Float / shares77.4%
Cash runway (months)0.6
Key info
SectorHealthcare
IndustryMedical - Pharmaceuticals
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001474167
AI Summary
AI-generated1/50
standardbullishearnings
Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million
Cosmos Health reported record preliminary nine-month 2026 revenue of approximately $54.3 million, up 19% year-over-year, with a record Q3 of approximately $17.4 million.
The company reaffirmed its full-year 2026 revenue outlook of more than $90 million, implying roughly 38% growth over 2025's $65.3 million, and expects Q4 to be its strongest quarter on record.
All figures are preliminary and unaudited; full Q3 results will come in the Form 10-Q. Growth was attributed to record contract manufacturing at Cana Laboratories, record distribution volumes at CosmoFarm, and expanding proprietary-brand sales.
Red flags
- Q3 revenue grew only ~2% YoY against the prior-year record, a sharp deceleration from prior 35-40% growth rates
- figures are preliminary and unaudited, subject to quarter-end closing procedures
- forward-looking statements reference digital asset strategies, tokenized financing programs, and pending investigations/litigation